Connective Tissue Dry Needling for Low Back Pain Related to Local Posterior Superior Iliac Spine Pain
Not yet recruitingNot applicableNCT07345871
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This single-blind randomized controlled trial will aim to determine the effectiveness of a connective tissue dry needling (CTDN) technique, in reducing pain and improving function in individuals with chronic mechanical low back pain associated with pain and tenderness at the posterior superior iliac spine (PSIS). Forty participants with local PSIS-related low back pain will be recruited and randomly assigned into two groups using the block balanced randomization method. The treatment group will receive CTDN targeting connective tissue trigger points around the PSIS in addition to a sacroiliac joint stabilization exercise program, while the control group will perform the same exercise program alone under the supervision of a physiotherapist. The intervention protocol will span two weeks, during which participants will attend three treatment sessions per week, for a total of six sessions. The primary outcome measurement will use the Visual Analog Scale (VAS) to assess pain intensity. The study will measure secondary outcomes through lumbar range of motion (ROM) in flexion and extension and pressure pain threshold (PPT), and Roland-Morris Disability Questionnaire (RMDQ) functional disability and Short Form-36 (SF-36) health-related quality of life. The researchers will assess all outcomes at three time points: baseline and after the first session, and the sixth session, while VAS will receive an additional assessment at the 3-month follow-up. The findings of this study are expected to provide evidence supporting CTDN as a safe, effective, and cost-efficient treatment option for PSIS-related mechanical low back pain.
Study details
- Official title
- Investigating the Effectiveness of Connective Tissue Dry Needling Technique on Patients With Low Back Pain Caused by Local Pain at Superior Posterior Iliac Spine: a Single-blind, Randomized Controlled Trial
- Conditions
- Chronic Low Back Pain (CLBP)
- Sacroiliac Joint Dysfunction
- Mechanical Low Back Pain
- Interventions
- Procedure: Connective tissue dry needling
- Procedure: Exercise therapy
- Sponsor
- University of Social Welfare and Rehabilitation Science
- Start date
- 2026-04-10
- Primary completion
- 2026-05-14
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion criteria: 1. Adults aged 18 to 75 years. 2. Diagnosed with chronic mechanical low back pain localized at the posterior superior iliac spine region. 3. Presence of point tenderness reproducible by palpation at the posterior superior iliac spine area. 4. Pain duration of at least two weeks, indicating the non-acute stage of low back pain. 5. Negative results in at least three out of five sacroiliac pain provocation tests (Distraction, Compression, Thigh Thrust, Sacral Thrust, Gaenslen). 6. Pain intensity ≥ 3 on the Numeric Rating Scale at baseline. 7. Ability to communicate and cooperate with the research team during intervention and follow-up. 8. Access to WhatsApp or equivalent communication application for follow-up pain reporting at the 3-month stage. Non-inclusion criteria: 1. Presence of lumbar radicular pain or referred pain to the lower limbs. 2. History of lumbar spine trauma within the previous three months. 3. Fear or intolerance of needling procedures. 4. Current use of anticoagulant medication. 5. Known lymphatic disorders, immunosuppressive diseases, or neurological conditions such as epilepsy or seizure disorders. 6. Pregnancy or suspected pregnancy. Exclusion criteria: 1. Voluntary withdrawal of consent at any time during the study. 2. Inability to tolerate the intervention or adverse reaction during treatment sessions. 3. Occurrence of serious adverse events or complications (e.g., infection, bleeding). 4. Non-compliance with treatment protocol or missing more than two sessions. 5. Any intercurrent illness or therapy that could interfere with the study outcomes or safety assessment
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07345871